Daily Chart

Johnson & Johnson (JNJ) Financial News - Drugmakers Seek End or Changes to U.S. Medication Naming Rules

Johnson & Johnson (JNJ)

Drugmakers Seek End or Changes to U.S. Medication Naming Rules

Quote: Johnson & Johnson (JNJ)GlaxoSmithKline Plc (GSK)post on Philly.com. Pennsylvania. “Without this set of eyes, there is little doubt that the number of serious errors could be far greater.” PhRMA agrees with Cohen that industry and other stakeholders should meet with the FDA to improve the process, said Jeffrey Francer, the group’s assistant general counsel. Those parties should determine how often name confusion contributes to medical errors and make the agency’s review process more transparent, moving decisions earlier to prevent approval delays, Francer said today in an interview. Revising Packaging The FDA said in June that J&J and Glaxo should revise packaging for drugs that have similar names after mix-ups sent at least five patients to the hospital for taking the wrong medication. New Brunswick, New Jersey-based J&J, and Requip, a medicine for Parkinson’s disease and restless-leg disorder made by London-based Glaxo. AstraZeneca Plc (AZN)Dexilant. Washingtonaedney@bloomberg.net. abettelheim@bloomberg.net. ...
Open whole article (external link)

Other Financial and Stock Market News concerning Johnson & Johnson

Johnson & Johnson Stock Summary

Stocktweeting is not a financial advisor, and in no way recommends the purchase of any stock or advise on the suitability of any trade or investment.
Stock trading and investing can cause loss of capital, and you should always consult with a professional financial advisor before trading or investing.

This website is a service of the HagensMedia ad network. For advertising please visit http://www.hagensmedia.com - Copyright 2015.